Co-treatment With Pegvisomant and a Somatostatin Analogue (SA) in SA-responsive Acromegalic Patients
Launched by UNIVERSITY OF AARHUS · Mar 31, 2008
Trial Information
Current as of May 06, 2025
Completed
Keywords
ClinConnect Summary
No description provided
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Age \> 18
- • Diagnosed with acromegaly
- • Safe anticonceptive for fertile women
- • Well controlled on somatostatin analog (a serum IGF-I within normal range a nadir GH \< 0.5 µg/l.)
- Exclusion Criteria:
- • Pregnancy
- • Liver disease
- • Diabetes mellitus type I
- • Magnetic or electronic implants
About University Of Aarhus
The University of Aarhus, a prestigious research institution located in Denmark, is dedicated to advancing medical science through innovative clinical trials. With a strong emphasis on interdisciplinary collaboration, the university fosters an environment that encourages cutting-edge research and the development of novel therapeutic interventions. Committed to ethical standards and patient safety, the University of Aarhus aims to contribute to the global body of medical knowledge while enhancing healthcare outcomes through rigorous scientific inquiry and evidence-based practices.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Aarhus C, Aarhus, Denmark
Aarhus C, Aarhus, Denmark
Patients applied
Trial Officials
Jens Otto L. Jørgensen, MD Professor
Principal Investigator
Aarhus University Hospital
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials